Jefferies Initiates Coverage On Artiva Biotherapeutics with Buy Rating, Announces Price Target of $21
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Kelly Shi has initiated coverage on Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy rating and set a price target of $21.

August 13, 2024 | 10:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies analyst Kelly Shi has initiated coverage on Artiva Biotherapeutics with a Buy rating and set a price target of $21.
The initiation of coverage with a Buy rating and a specific price target of $21 by a reputable analyst from Jefferies is likely to positively impact the stock price of Artiva Biotherapeutics in the short term. Such analyst actions often lead to increased investor interest and buying activity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100